Chemomab Therapeutics

CMMB

時価総額 $923万

TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for immune-fibrotic diseases with high unmet need, today announced that Chief Executive Officer Dr. Adi Mor will deliver a corporate presentation at the H.C.

Planned merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in RA continues to advance with closing expected by year-end

Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript

Chemomab and Scipher announced a merger agreement to advance nebokitug into a Phase 2 precision medicine trial for the treatment of rheumatoid arthritis.

—New C linical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary Sclerosing Cholangitis and Suggests Possible Additional Benefit in PSC Patients with Co-Existing IBD— —Company Continues to Advance Multiple Partnering Options for Nebokitug— TEL AVIV, Israel, May 14, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2026, and provided a corporate update.

2025 was a critical year for Chemomab and nebokitug. Partnering discussions continue to advance along with preparations to launch the PSC Phase 3 trial.

TEL AVIV, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that CEO Dr. Adi Mor and other members of its senior management team will deliver a corporate presentation and participate in one-on-one investor meetings at the virtual Oppenheimer 36 th Annual Healthcare Life Sciences Conference on February 26, 2026.

— New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports Advancement to a P hase 3 Registration Trial — TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the results of its Phase 2 SPRING trial assessing nebokitug in patients with primary sclerosing cholangitis (PSC) were published in the current issue of the American Journal of Gastroenterology.1 The study showed that nebokitug was generally safe and well tolerated in patients with PSC for up to 48 weeks of treatment.

TEL AVIV, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that co-founder and CEO Adi Mor, PhD, will participate in Oppenheimer's Movers in Rare Disease Summit on Thursday, December 11, 2025, at the Sofitel Hotel in New York City.

—Nebokitug PSC Phase 3 Design Near Completion Following Positive FDA Feedback— —Regulatory Alignment Advances, with EMA Guidance Supporting a Single Nebokitug Phase 3 Registration Trial Using a Clinical Event Composite Endpoint — —Phase 2 SPRING Trial OLE Data Showing Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks Presented at AASLD 2025 — — New Clinical Data Presented at AASLD 2025 Provides Insights on Nebokitug's Direct Macrophage-Mediated Mechanisms that Are Relevant to Halting or Slowing PSC Disease Progression— —Multiple Partnering Options for Supporting the Nebokitug Phase 3 Program Continue to Advance— —Cash Runway Expected through End of Fourth Quarter of 2026— TEL AVIV, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the third quarter ended September 30, 2025, and provided a corporate update.